Market Place
Sourcing Support
Biosplice Initiates NCI-Sponsored AML And MDS Trial
12 Sep 2024 //
GLOBENEWSWIRE
Biosplice, Novo Nordisk Partner to Develop Drug for Treatment of Diabetes
13 Jun 2024 //
CONTRACT PHARMA
Biosplice searches for a path forward osteoarthritis drug fails late-stage study
22 Apr 2024 //
ENDPTS
Biosplice: OA-07 P3 Lorecivivint Data At OARSI, OA-21 12-Wk Results
18 Apr 2024 //
GLOBENEWSWIRE
Biosplice Therapeutics Announces Department of Defense (DoD) Award
08 Mar 2024 //
GLOBENEWSWIRE
Biosplice announces data from phase 3 trial in knee osteoarthritis
17 Dec 2022 //
PHARMABIZ
Biosplice Announces Data from Phase 3 Trial in Knee Osteoarthritis
15 Dec 2022 //
GLOBENEWSWIRE
Biosplice Announces Data from Recent Trials in Knee Osteoarthritis Ph 3 Trial
11 Nov 2022 //
GLOBENEWSWIRE
Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502)
29 Sep 2022 //
GLOBENEWSWIRE
$12B biotech Biosplice lays off 41, axes hair loss asset
09 Feb 2022 //
FIERCEBIOTECH
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial
17 Nov 2021 //
GLOBENEWSWIRE
Biosplice Licenses Rights for Lorecivivint to Haisco for China
15 Sep 2021 //
GLOBENEWSWIRE
Biosplice Phase 2B Lorecivivint Clinically Meaningful to Knee Osteoarthritis
22 Jul 2021 //
GLOBENEWSWIRE
Biosplice Phase 2B Lorecivivint Clinically Meaningful to Knee Osteoarthritis
22 Jul 2021 //
GLOBENEWSWIRE
Dave Johnson Joins Biosplice Therapeutics Board of Directors
21 Jun 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.